GlassScriptPhysician profile
Sarpreet Ssingh Basra
NPI 1427224765
$9,994.55
in general payments reported to CMS, 2019-2025
30 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,531 · 2020: $355 · 2021: $1,400 · 2022: $1,563 · 2023: $1,611 · 2024: $1,651 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,719 · Education: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,718.63 |
| Education | $427.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,262.94 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,673.38 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $674.88 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $627.69 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $586.79 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $559.29 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $534.05 | 2019-2025 | |
| Gilead Sciences, INC. | $440.92 | 2019-2025 | |
| Qol Medical, LLC | $236.77 | 2022-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $213.96 | 2019-2025 | |
| Allergan, INC. | $196.66 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $132.65 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $123.87 | 2019 | |
| Medtronic, INC. | $109.35 | 2021 | |
| Ferring Pharmaceuticals INC. | $108.51 | 2019-2025 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $89.69 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $82.96 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $48.61 | 2021-2022 | |
| Novo Nordisk INC | $35.02 | 2025 | Wegovy |
| Exact Sciences Corporation | $33.81 | 2025 | The Cologuard Plus Collection Kit |
| Ipsen Biopharmaceuticals, INC | $31.90 | 2024-2025 | Bylvay |
| Ironwood Pharmaceuticals, INC | $30.57 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $28.96 | 2025 | |
| Apollo Endosurgery US INC | $27.48 | 2021 | |
| Daiichi Sankyo INC. | $19.35 | 2019 | |
| Lilly USA, LLC | $18.78 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $18.59 | 2024 | |
| Ambu INC. | $17.87 | 2021 | |
| Shield Therapeutics INC | $16.24 | 2024 | |
| Boston Scientific Corporation | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarpreet Basra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.